Alere

Investment banks Canaccord Genuity and Raymond James also raised their price targets on the company.

Abbott said that greater than 90 percent of the issued and outstanding shares of preferred stock had been tendered as of Sept. 15.

The firm extended its cash tender offer for all outstanding shares of Alere's Series B convertible perpetual preferred stock until the end of the day on Sept. 15.

The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.

Alere's financial results in the prior-year period reflected restatements of revenues stemming from incorrectly recorded revenue transactions.

Canaccord and William Blair also increased their price targets on  Quidel's shares, following its acquisition of certain Alere assets and assays.

About 63 million votes were in favor of the deal, representing more than 72.5 percent of all outstanding Alere shares as of the May 31 record date.

Sales for its cardiometabolic tests dropped sharply, while sales for its flu tests soared and its consumer diagnostics sales were flat.

The firm's Q4 global influenza sales were up 60 percent year over year, and in 2016 its global infectious disease business achieved double-digit sales growth.

Pages

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.